688488 艾迪药业
已收盘 08-20 15:00:01
资讯
新帖
简况
艾迪药业（688488）披露实际控制人之一致行动人部分股份质押公告，8月18日股价下跌2.32%
证券之星 · 08-18 22:10
艾迪药业（688488）披露实际控制人之一致行动人部分股份质押公告，8月18日股价下跌2.32%
艾迪药业（688488）股东傅和祥质押450万股，占总股本1.07%
证券之星 · 08-18 18:26
艾迪药业（688488）股东傅和祥质押450万股，占总股本1.07%
每周股票复盘：艾迪药业（688488）完成收购南大药业少数股权
证券之星 · 08-16
每周股票复盘：艾迪药业（688488）完成收购南大药业少数股权
股市必读：艾迪药业新发布《艾迪药业关于公司收购控股子公司少数股东股权进展的公告》
证券之星 · 08-14
股市必读：艾迪药业新发布《艾迪药业关于公司收购控股子公司少数股东股权进展的公告》
艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，8月12日股价下跌1.16%
证券之星 · 08-12
艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，8月12日股价下跌1.16%
每周股票复盘：艾迪药业（688488）董事傅和亮增持7.06万股
证券之星 · 08-09
每周股票复盘：艾迪药业（688488）董事傅和亮增持7.06万股
8月7日艾迪药业涨8.54%，华商科创创业精选混合A基金重仓该股
证券之星 · 08-07
8月7日艾迪药业涨8.54%，华商科创创业精选混合A基金重仓该股
8月4日艾迪药业涨5.99%，华商科创创业精选混合A基金重仓该股
证券之星 · 08-04
8月4日艾迪药业涨5.99%，华商科创创业精选混合A基金重仓该股
艾迪药业：7月31日董事傅和亮增持股份合计7.06万股
证券之星 · 08-03
艾迪药业：7月31日董事傅和亮增持股份合计7.06万股
7月30日艾迪药业跌8.15%，华商科创创业精选混合A基金重仓该股
证券之星 · 07-30
7月30日艾迪药业跌8.15%，华商科创创业精选混合A基金重仓该股
艾迪药业：7月27日董事傅和亮增持股份合计13.28万股
证券之星 · 07-28
艾迪药业：7月27日董事傅和亮增持股份合计13.28万股
7月27日艾迪药业涨6.13%，华商科创创业精选混合A基金重仓该股
证券之星 · 07-27
7月27日艾迪药业涨6.13%，华商科创创业精选混合A基金重仓该股
艾迪药业获得发明专利授权：“一种尤瑞克林残留蛋白的检测试剂盒及其制备方法和应用”
证券之星 · 07-25
艾迪药业获得发明专利授权：“一种尤瑞克林残留蛋白的检测试剂盒及其制备方法和应用”
7月24日艾迪药业跌5.00%，华商科创创业精选混合A基金重仓该股
证券之星 · 07-24
7月24日艾迪药业跌5.00%，华商科创创业精选混合A基金重仓该股
艾迪药业最新公告：达芦那韦片获得药品注册批准
证券之星 · 07-23
艾迪药业最新公告：达芦那韦片获得药品注册批准
7月17日艾迪药业跌9.49%，兴全合兴LOF基金重仓该股
证券之星 · 07-17
7月17日艾迪药业跌9.49%，兴全合兴LOF基金重仓该股
7月15日艾迪药业涨9.22%，兴全合兴LOF基金重仓该股
证券之星 · 07-15
7月15日艾迪药业涨9.22%，兴全合兴LOF基金重仓该股
每周股票复盘：艾迪药业（688488）ADC119片获临床试验批准
证券之星 · 07-12
每周股票复盘：艾迪药业（688488）ADC119片获临床试验批准
艾迪药业(688488.SH)：ADC119片获得药物临床试验批准通知书
智通财经 · 07-08
艾迪药业(688488.SH)：ADC119片获得药物临床试验批准通知书
艾迪药业：公司持续推进海外渠道布局与市场拓展相关工作
证券之星 · 07-07
艾迪药业：公司持续推进海外渠道布局与市场拓展相关工作
加载更多
公司概况
公司名称：
江苏艾迪药业集团股份有限公司
所属行业：
其他制造业
上市日期：
2020-07-20
主营业务：
江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是乌司他丁粗品、其他人源蛋白粗品、HIV新药(艾诺韦林片)、HIV新药(艾诺米替片)、番泻叶颗粒、蜡样芽孢杆菌片、药品（尿激酶针剂）、低分子量肝素钠及其他。
发行价格：
13.99
{"stockData":{"symbol":"688488","market":"SH","secType":"STK","nameCN":"艾迪药业","latestPrice":17.16,"timestamp":1787209201000,"preClose":17.85,"halted":0,"volume":19172401,"delay":0,"changeRate":-0.0387,"floatShares":421000000,"shares":421000000,"eps":-0.0654,"marketStatus":"已收盘","change":-0.69,"latestTime":"08-20 15:00:01","open":18.51,"high":18.88,"low":17.07,"amount":342000000,"amplitude":0.1014,"askPrice":17.17,"askSize":45,"bidPrice":17.16,"bidSize":14,"shortable":0,"etf":0,"ttmEps":-0.0654,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"adjPreClose":17.85,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787189400000,1787196600000],[1787202000000,1787209200000]],"highLimit":19.64,"lowLimit":16.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":420782808,"isCdr":false,"pbRate":7.41,"roa":"--","roe":"0.78%","epsLYR":-0.05,"committee":-0.18624,"marketValue":7221000000,"turnoverRate":0.0456,"status":1,"afterMarket":{"amount":3432,"volume":200,"close":17.16,"buyVolume":3700,"sellVolume":0,"time":1787211237746,"indexStatus":"已收盘 08-20 15:30:00","preClose":17.85},"floatMarketCap":7221000000},"requestUrl":"/m/hq/s/688488","defaultTab":"news","newsList":[{"id":"2660049871","title":"艾迪药业（688488）披露实际控制人之一致行动人部分股份质押公告，8月18日股价下跌2.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660049871","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660049871?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:10","pubTimestamp":1787062234,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，艾迪药业报收于17.3元，较前一交易日下跌2.32%，最新总市值为72.8亿元。近日，艾迪药业发布关于实际控制人之一致行动人部分股份质押的公告。公告显示，公司实际控制人傅和亮先生的一致行动人傅和祥先生持有公司股份13,179,944股，占公司总股本的3.13%。本次质押股份4,500,000股，占其所持股份的34.14%，占公司总股本的1.07%。质权人为深圳市深担增信融资担保有限公司，质押起始日为2026年8月17日，到期日以质权人申请解除质押为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800042298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469920","title":"艾迪药业（688488）股东傅和祥质押450万股，占总股本1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469920","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660469920?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:26","pubTimestamp":1787048794,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业8月18日公开信息显示，股东傅和祥向深圳市深担增信融资担保有限公司合计质押450.0万股，占总股本1.07%。质押详情见下表：截止本公告日，股东傅和祥已累计质押股份450.0万股，占其持股总数的34.14%。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。本文数据来源于艾迪药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800035159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175970","title":"每周股票复盘：艾迪药业（688488）完成收购南大药业少数股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175970","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175970?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:40","pubTimestamp":1786815621,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，艾迪药业报收于18.15元，较上周的17.54元上涨3.48%。本周关注点来自公司公告汇总：艾迪药业完成收购南大药业22.2324%少数股权，持股比例升至73.3580%。公司公告汇总艾迪药业已完成收购控股子公司南京南大药业有限责任公司少数股东华泰国信、道兴创投及姚繁狄合计持有的22.2324%股权。本次交割完成后，艾迪药业持有南大药业73.3580%股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659615851","title":"股市必读：艾迪药业新发布《艾迪药业关于公司收购控股子公司少数股东股权进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659615851","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659615851?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:55","pubTimestamp":1786643715,"startTime":"0","endTime":"0","summary":"公司公告汇总：艾迪药业已完成收购南大药业22.2324%少数股权，持股比例升至73.3580%，相关工商变更及董事会调整已落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658973566","title":"艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，8月12日股价下跌1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658973566","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658973566?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:22","pubTimestamp":1786526566,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，艾迪药业报收于17.08元，较前一交易日下跌1.16%，最新总市值为71.87亿元。近日，艾迪药业发布《关于公司收购控股子公司少数股东股权进展的公告》。公告显示，江苏艾迪药业集团股份有限公司已完成收购控股子公司南京南大药业有限责任公司少数股东华泰国信、道兴创投及姚繁狄合计持有的22.2324%股权。本次交割完成后，艾迪药业持有南大药业73.3580%股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200029234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658067526","title":"每周股票复盘：艾迪药业（688488）董事傅和亮增持7.06万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658067526","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658067526?lang=zh_cn&edition=full","pubTime":"2026-08-09 03:20","pubTimestamp":1786216820,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，艾迪药业报收于17.54元，较上周的13.83元上涨26.83%。本周，艾迪药业8月7日盘中最高价报17.74元。8月3日盘中最低价报12.99元。艾迪药业当前最新总市值73.81亿元，在生物制品板块市值排名35/51，在两市A股市值排名2336/5205。本周关注点股本股东变化：董事傅和亮于7月31日增持7.06万股，占总股本0.0168%。变动期间公司股价上涨2.22%，当日收盘价为13.83元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900001157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616321","title":"8月7日艾迪药业涨8.54%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616321","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616321?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:42","pubTimestamp":1786092161,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日艾迪药业涨8.54%，收盘报17.54元，换手率4.15%，成交量17.46万手，成交额2.97亿元。重仓艾迪药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262","159781"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656953649","title":"8月4日艾迪药业涨5.99%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656953649","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656953649?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:43","pubTimestamp":1785832993,"startTime":"0","endTime":"0","summary":"证券之星消息，8月4日艾迪药业涨5.99%，收盘报13.98元，换手率2.24%，成交量9.42万手，成交额1.3亿元。重仓艾迪药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400027731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488","159781"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656443376","title":"艾迪药业：7月31日董事傅和亮增持股份合计7.06万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656443376","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656443376?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:01","pubTimestamp":1785758491,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月3日市场公开信息、上市公司公告及交易所披露数据整理，艾迪药业最新董监高及相关人员股份变动情况：2026年7月31日公司董事,核心技术人员傅和亮共增持公司股份7.06万股，占公司总股本为0.0168%。艾迪药业近半年内的董监高及核心技术人员增减持详情如下：艾迪药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出859.37万，融资余额减少；融券净流出1600.0，融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300032145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655282421","title":"7月30日艾迪药业跌8.15%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655282421","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655282421?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:43","pubTimestamp":1785400999,"startTime":"0","endTime":"0","summary":"证券之星消息，7月30日艾迪药业跌8.15%，收盘报13.53元，换手率2.76%，成交量11.61万手，成交额1.63亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A目前规模为1.96亿元，最新净值1.9474，较上一交易日下跌0.86%。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000026023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262","159781"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017770","title":"艾迪药业：7月27日董事傅和亮增持股份合计13.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017770","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654017770?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:01","pubTimestamp":1785240104,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月28日市场公开信息、上市公司公告及交易所披露数据整理，艾迪药业最新董监高及相关人员股份变动情况：2026年7月27日公司董事,核心技术人员傅和亮共增持公司股份13.28万股，占公司总股本为0.0316%。变动期间公司股价上涨6.13%，7月27日当日收盘报15.92元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800036019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654013648","title":"7月27日艾迪药业涨6.13%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654013648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654013648?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:41","pubTimestamp":1785141719,"startTime":"0","endTime":"0","summary":"证券之星消息，7月27日艾迪药业涨6.13%，收盘报15.92元，换手率2.68%，成交量11.28万手，成交额1.75亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A目前规模为1.96亿元，最新净值2.0104，较上一交易日上涨0.48%。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700020970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159781","688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654342590","title":"艾迪药业获得发明专利授权：“一种尤瑞克林残留蛋白的检测试剂盒及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2654342590","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654342590?lang=zh_cn&edition=full","pubTime":"2026-07-25 03:40","pubTimestamp":1784922043,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示艾迪药业新获得一项发明专利授权，专利名为“一种尤瑞克林残留蛋白的检测试剂盒及其制备方法和应用”，专利申请号为CN202610561279.3，授权日为2026年7月24日。本发明填补尿源蛋白药物残留蛋白检测空白，特异性强，抗体覆盖率达到70%以上，方法定量限为4ng/ml左右，对于尤瑞克林的残留蛋白检测限低、检测灵敏度高，无需昂贵仪器，操作简便。今年以来艾迪药业新获得专利授权2个，较去年同期增加了100%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072500003048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653394700","title":"7月24日艾迪药业跌5.00%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653394700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653394700?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:42","pubTimestamp":1784882548,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日艾迪药业跌5.00%，收盘报15.0元，换手率2.38%，成交量10.03万手，成交额1.55亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A目前规模为1.96亿元，最新净值2.0008，较上一交易日下跌3.55%。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262","159781"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653404747","title":"艾迪药业最新公告：达芦那韦片获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2653404747","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653404747?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:00","pubTimestamp":1784808054,"startTime":"0","endTime":"0","summary":"艾迪药业(688488.SH)公告称，近日，公司收到国家药监局核准签发的达芦那韦片《药品注册证书》。达芦那韦片是公司获批的又一款抗HIV领域治疗药物，系国内首仿获批品种，且国内目前暂无其他含达芦那韦活性成分药物上市销售。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300043612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652054214","title":"7月17日艾迪药业跌9.49%，兴全合兴LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652054214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652054214?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:30","pubTimestamp":1784277044,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日艾迪药业跌9.49%，收盘报15.36元，换手率4.62%，成交量19.43万手，成交额3.01亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共12家，其中持有数量最多的公募基金为兴证全球基金的兴全合兴LOF。陈宇在任的基金产品包括:兴全精选混合，管理时间为2017年9月6日至今，期间收益率为225.78%；兴全合兴LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["163418","688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651536564","title":"7月15日艾迪药业涨9.22%，兴全合兴LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651536564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651536564?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:23","pubTimestamp":1784103833,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日艾迪药业涨9.22%，收盘报17.17元，换手率8.35%，成交量35.12万手，成交额6.15亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共12家，其中持有数量最多的公募基金为兴证全球基金的兴全合兴LOF。陈宇在任的基金产品包括:兴全精选混合，管理时间为2017年9月6日至今，期间收益率为223.1%；兴全合兴LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262","163418"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650115401","title":"每周股票复盘：艾迪药业（688488）ADC119片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2650115401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650115401?lang=zh_cn&edition=full","pubTime":"2026-07-12 03:12","pubTimestamp":1783797130,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，艾迪药业报收于14.32元，较上周的14.2元上涨0.85%。本周，艾迪药业7月6日盘中最高价报16.19元。本周关注点公司公告汇总：抗艾滋病新药ADC119片获临床试验批准。公司公告汇总艾迪药业关于ADC119片获得药物临床试验批准通知书的自愿性披露公告江苏艾迪药业集团股份有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研2.3类改良型新药ADC119片开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200001189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649299623","title":"艾迪药业(688488.SH)：ADC119片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2649299623","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649299623?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:01","pubTimestamp":1783515680,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾迪药业 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研2.3类改良型新药ADC119片开展临床试验。ADC119 片可通过抑制 HIV 逆转录酶，阻断病毒RNA向DNA的逆转录过程，有效抑制 HIV-1 病毒的复制，临床拟用于治疗HIV-1 感染。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688488","BK0262","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649898615","title":"艾迪药业：公司持续推进海外渠道布局与市场拓展相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649898615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649898615?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:48","pubTimestamp":1783417700,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业(688488)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问非洲等海外市场销售网络搭建及产品进展如何？是否会影响2026年海外收入在总营收中的占比？艾迪药业回复：尊敬的投资者，您好。公司持续推进海外渠道布局与市场拓展相关工作，现阶段海外商业化仍处于前期培育阶段，相关业务经营数据请以公司后续定期报告及官方公告为准。感谢您对公司的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700030596.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787215386071,"stockEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":0.117},{"period":"3month","weight":0.1319},{"period":"6month","weight":0.02},{"period":"1year","weight":0.0068},{"period":"ytd","weight":0.0931}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":0.0259},{"period":"3month","weight":-0.0448},{"period":"6month","weight":-0.046},{"period":"1year","weight":0.0448},{"period":"ytd","weight":-0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏艾迪药业集团股份有限公司","boardCode":"AI0041","boardName":"其他制造业","stockholders":"11700人(较上一季度增加7.33%)","perCapita":"35964股","listingDate":"2020-07-20","address":"江苏省扬州市邗江区新甘泉西路69号","registeredCapital":"42078万元","survey":" 江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是乌司他丁粗品、其他人源蛋白粗品、HIV新药(艾诺韦林片)、HIV新药(艾诺米替片)、番泻叶颗粒、蜡样芽孢杆菌片、药品（尿激酶针剂）、低分子量肝素钠及其他。","listedPrice":13.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪药业,688488,艾迪药业股票,艾迪药业股票老虎,艾迪药业股票老虎国际,艾迪药业行情,艾迪药业股票行情,艾迪药业股价,艾迪药业股市,艾迪药业股票价格,艾迪药业股票交易,艾迪药业股票购买,艾迪药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}